Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Ponatinib & Acute Lymphoblastic Leukemia (ALL) (Ph+ ALL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Regulatory status

In the context of Ponatinib & Acute Lymphoblastic Leukemia (ALL) (Ph+ ALL), ponatinib a third-generation TKI is FDA‑approved for Acute Lymphoblastic Leukemia (ALL) (Ph+ ALL), both in the front‑line combination setting and in later‑line monotherapy‑like indications (1, 2)

References

(1) fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome
(2) Pavlovsky et al. 2019 Future Oncology 15: 257–269

…

References (Sources)

Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
Pavlovsky et al. 2019 Future Oncology 15: 257–269

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!